TG 1050

Drug Profile

TG 1050

Alternative Names: TG-1050

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Transgene
  • Developer Transgene; Transgene - Tasly Pharmaceutics Group (JV)
  • Class Hepatitis B vaccines; Peptide vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 24 Oct 2017 Efficacy data from a phase I/Ib trial in Hepatitis B presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 23 Oct 2017 Adverse events and immunogenicity data from a phase I/Ib trial in Hepatitis B released by Transgene (NCT02428400)
  • 17 Oct 2017 Transgene completes enrolment in its phase I/Ib trial for Hepatitis B in France, Canada and Germany (NCT02428400)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top